The age-adjusted incidence and death rates for ovarian cancer are 13.3 and 8.8 per 100,000, respectively. The average five-year survival rate for ovarian cancer patients

is ~46%. This high overall mortality is a consequence of a failure to detect this disease at an early stage. As there are no clinically overt early symptoms, most women (~75%) are first diagnosed with disseminated disease (Stage III/IV) when prognosis is poor. Despite recent progress in chemotherapeutic treatments, the diagnosis of late stage disease is associated with a five-year survival rate of ~30%. In contrast, when ovarian cancer is identified at an early stage, five year survival increases to ~90%. Thus, the development of more accurate PND-1186 purchase and earlier detection tests for this disease are undoubtedly the number one priority for achieving long-term reduction of mortality from ovarian cancer

[1]. Currently, plasma or serum CA125 concentration is the best characterised and most widely used ovarian cancer biomarker and is elevated in more than 80% of patients with epithelial ovarian cancer [2]. CA125 concentrations, however, are increased in only ~ 50% of patients with Stage I disease [3]. Thus, more accurate and earlier detection tests are requisite to reducing the mortality associated with this disease. Previously, we and others have reported the utility of combining biomarkers MK-8931 solubility dmso to develop classification algorithms for identifying CYTH4 women with ovarian cancer [4–10]. Such this website studies establish proof-of-concept and the potential to improve diagnostic efficiency by combining multiple ovarian cancer biomarkers. The sensitivity and specificity of such panels, however, must be further improved and additional informative biomarkers that contribute to multivariate modelling need to be identified. The purpose of this study was to characterise changes in the plasma concentrations of MDK in association

with ovarian cancer and compare its diagnostic performance (as assessed by the AUC) with that of AGR2 (a recently reported circulating biomarker of ovarian cancer [11]) and CA125 in symptomatic women. Available data are consistent with a putative role for both AGR2 and MDK in oncogenesis and tumor progression, including ovarian cancer. Materials and methods Control and ovarian cancer plasma samples Plasma samples were collected from healthy women (median age 52, range 32-69 years, n = 61) and women at the time of diagnosis of ovarian cancer and before treatment (median age 61, range 24-69 years, n = 46). The project was approved by the Mercy Hospital for Women Human Research and Ethics Committee (R09/06). All case samples and part of the control sample set used in this study were provided by the Biobank at Peter MacCallum Cancer Research Institute (Melbourne, Australia) and all subjects participated in the study after signing an informed written consent.